Surveillance of ischemic stroke recurrence after prescription of EFIENT tablets (prasugrel)-JMDC Cohort Study-

JRCT ID: jRCT2031230289

Registered date:12/08/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Ischemic stroke
• Date of first enrollment: 01/01/2005
• Target sample size: 1300
• Study type: Observational

Outcome(s)

• Primary Outcome: Ischemic stroke recurrence

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) Patients who have prescription of prasugrel or clopidogrel within the enrollment period (December 24, 2021 to May 31, 2027). The cohort entry date: first prescription date of prasugrel or clopidogrel within the enrollment period.
2) Patients with acute ischemic stroke treated in hospital have diagnosis of atherothrombotic stroke or lacunar stroke during the past 30 days from the day before the cohort entry date.
3) Patients who have risk factors for ischemic stroke recurrence.
4) Patients who have medical records for the past 90 days from the day before the cohort entry date (Look back period).

Exclude criteria

1) Patients who have prescription of prasugrel or clopidogrel in the look back period.
2) No medical records from the day after the cohort entry date.
3) Patients who have prescriptions of prasugrel and clopidogrel on the cohort entry date.

Related Information

• Primary Sponsor: Tanabe Hirokazu